Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma

International Journal of Gynecological Cancer

Volumn 15, Issue 2, 2005, Pages 329-336

  Arita, S ^a   Kikkawa, F ^a   Kajiyama, H ^a   Shibata, K ^a   Kawai, M ^b   Mizuno, K ^c   Nagasaka, T ^a   Ino, K ^a   Nomura, S ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^c JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

Carcinosarcoma; Endometrial stromal sarcoma; flk 1; flt 1; Leiomyosarcoma; VEGF

Indexed keywords

VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARCINOSARCOMA; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOMETRIUM SARCOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEIOMYOSARCOMA; MYOMETRIUM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STAINING; SURVIVAL RATE; UTERUS SARCOMA;

ADULT; AGED; CARCINOSARCOMA; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MIDDLE AGED; MUSCLE, SMOOTH; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SARCOMA; SARCOMA, ENDOMETRIAL STROMAL; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 15444376279     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.15225.x     Document Type: Article

References (37)

1. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994;18:535-58.
2. Pautier P, Genestie C, Rey A et al. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 2000;88:1425-31.
3. Amant F, Vergote I. PTEN mutation analysis in uterine leiomyosarcomas and mixed mullerian sarcomas. Am J Obstet Gynecol 2002;187:258.
4. Amant F, de la Rey M, Dorfling CM et al. PTEN mutations in uterine sarcomas. Gynecol Oncol 2002;85:165-9.
5. Lancaster JM, Risinger JI, Carney ME, Barrett JC, Berchuck A. Mutational analysis of the PTEN gene in human uterine sarcomas. Am J Obstet Gynecol 2001;184:1051-3.
6. Levy B, Mukherjee T, Hirschhorn K. Molecular cytogenetic analysis of uterine leiomyoma and leiomyosarcoma by comparative genomic hybridization. Cancer Genet Cytogenet 2000;121:1-8.
7. Yoshida Y, Kurokawa T, Fukuno N, Nishikawa Y, Kamitani N, Kotsuji F. Markers of apoptosis and angiogenesis indicate that carcinomatous components play an important role in the malignant behavior of uterine carcinosarcoma. Hum Pathol 2000;31:1448-54.
8. Saito H, Tsujitani S, Kondo A, Ikeguchi M, Maeta M, Kaibara N. Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma. Surgery 1999;125:195-201.
9. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-8.
10. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
11. Graeven U, Fiedler W, Karpinski S et al. Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. J Cancer Res Clin Oncol 1999;125:621-9.
12. Speirs V, Atkin SL. Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours. Br J Cancer 1999;80:898-903.
13. Boocock CA, Charnock-Jones DS, Sharkey AM et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995;87:506-16.
14. Fine BA, Valente PT, Feinstein GI, Dey T. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma. Gynecol Oncol 2000;76:33-9.
15. Giatromanolaki A, Koukourakis MI, Kakolyris S et al. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 1998;4:3017-24.
16. Nakopoulou L, Stefanaki K, Panayotopoulou E et al. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Hum Pathol 2002;33:863-70.
17. Ferrer FA, Miller LJ, Lindquist R et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 1999;54:567-72.
18. de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol 1998;184:53-7.
19. Strizzi L, Catalano A, Vianale G et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468-75.
20. Bachelder RE, Crago A, Chung J et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001;61:5736-40.
21. Bellamy WT, Richter L, Sirjani D et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001;97:1427-34.
22. Dias S, Hattori K, Heissig B et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 2001;98:10857-62.
23. Broggini M, Marchini SV, Galliera E et al. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 2003;17:52-9.
24. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 2001;85:273-8.
25. Shalaby F, Ho J, Stanford WL et al. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell 1997;89:981-90.
26. Brown LF, Detmar M, Tognazzi K, Abu-Jawdeh G, Iruela-Arispe ML. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor. Lab Invest 1997;76:245-55.
27. Ito N, Wernstedt C, Engstrom U, Claesson-Welsh L. Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules. J Biol Chem 1998;273:23410-8.
28. Rahimi N, Dayanir V, Lashkari K. Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J Biol Chem 2000;275:16986-92.
29. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996;226:324-8.
30. Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R. p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer 2000;89:51-62.
31. Koukourakis MI, Giatromanolaki A, Thorpe PE et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 2000;60:3088-95.
32. Edmonson JH, Blessing JA, Cosin JA, Miller DS, Cohn DE, Rotmensch J Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol 2002;85:507-10.
33. Gallup DG, Blessing JA, Andersen W, Morgan MA. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 2003;89:48-51.
34. Rose PG, Blessing JA, Soper JT, Barter JF. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 1998;70:267-71.
35. Toi M, Bando H, Ogawa T, Muta M, Hornig C, Weich HA. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer 2002;98:14-8.
36. Hasumi Y, Mizukami H, Urabe M et al. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res 2002;62:2019-23.
37. Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000;60:5117-24.